ABVC - ABVC Biopharma rises 18% on acceleration of ADHD drug Phase 2 trial
- ABVC Biopharma ( NASDAQ: ABVC ) is surging ~18% premarket after the company enrolled a total of 22 subjects in the Phase II Part II clinical study of the its attention-deficit hyperactivity disorder drug, ABV-1505.
- The company expects to eventually enroll about 100 patients for the study.
- The company said one of the enrolled participants from the three arms completed the 8-week treatment as per the study design.
- Five research hospitals in Taiwan and the research hospital at the University of California, San Francisco are a part in the study, which is a continuation of the Phase II Part I study of ABV-1505.
- The ADHD drug market is valued at $16.4B in 2018 and expected to reach $24.9B by 2025, according to Grand View Research’s market research report.
For further details see:
ABVC Biopharma rises 18% on acceleration of ADHD drug Phase 2 trial